Nephrotic Syndrome and Podocytopathies — Advanced

Anti-PLA2R antibody testing is the most useful non‑invasive test to support a diagnosis of primary (autoimmune) membranous nephropathy: a positive test strongly suggests primary disease and correlates with disease activity. Complement levels (option B) are more helpful in complement‑mediated glomerulopathies and are typically normal in primary membranous nephropathy. Anti-THSD7A (option C) is another autoantibody that can be positive in a minority of primary membranous cases but is less sensitive than anti-PLA2R and is not the first-line test. Monoclonal protein screening (option D) is appropriate when secondary causes such as light‑chain amyloidosis or monoclonal gammopathy are suspected, but it does not distinguish primary membranous disease specifically. Renal biopsy (option E) remains the diagnostic gold standard and will confirm membranous nephropathy and exclude other histologies, but in many adults with suspected membranous disease a positive anti-PLA2R result informs diagnosis and may guide timing of biopsy and management; therefore serology is a useful next investigation. In summary, anti-PLA2R is the best initial test to support primary membranous nephropathy in this context.

In adults with new‑onset nephrotic syndrome, a renal biopsy is indicated to establish the histological diagnosis before instituting disease‑directed immunosuppression because the differential includes multiple histologies (membranous nephropathy, FSGS, minimal change, amyloid, etc.) that require different therapies. Empirical high‑dose steroids (option A) are appropriate in many children but not adults without biopsy confirmation. Starting an ACE inhibitor (option B) is good supportive care for proteinuria but does not replace the need for histological diagnosis if immunosuppression is being considered. Immediate rituximab (option D) without histological confirmation or serological markers (e.g., anti‑PLA2R) is not appropriate. Routine upfront genetic testing (option E) is not the initial step in an adult without features suggestive of monogenic disease (early onset, family history, extrarenal features); genetic testing is considered in steroid‑resistant disease or when the clinical picture suggests a genetic cause. Therefore, renal biopsy is the correct next step prior to disease‑specific immunosuppression.

In nephrotic patients with diuretic resistance related to severe hypoalbuminaemia, a commonly used strategy is to give intravenous albumin to restore intravascular oncotic pressure followed promptly by an intravenous loop diuretic to increase natriuresis and fluid mobilization. This approach can transiently improve diuretic effectiveness. Simply increasing oral furosemide (option A) while the patient is diuretic‑resistant and likely has poor bioavailability is unlikely to be effective. Spironolactone alone (option B) or a thiazide‑type diuretic alone (option C) may be used as part of sequential nephron blockade (combination therapy) but are less effective as single agents in tense oedema and do not address hypoalbuminaemia. Extracorporeal ultrafiltration (option E) is a rescue therapy for severe refractory fluid overload and generally reserved for cases unresponsive to aggressive medical management or when there are contraindications; it is not the immediate next step. Note that albumin infusion should be used selectively and with close monitoring of intravascular volume and renal function.

Severe hypoalbuminaemia is the most important and reproducible risk factor for venous thromboembolism in nephrotic syndrome; low oncotic pressure, loss of anticoagulant proteins in the urine and increased hepatic synthesis of procoagulant factors contribute to a prothrombotic state. A history of minor haematuria (option B) or controlled hypertension (option C) are not major drivers of VTE risk in this context. Elevated LDL (option D) is associated with atherothrombotic risk but not the acute venous thromboembolism risk seen in nephrotic syndrome. A bland or microscopic urinary sediment (option E) does not predict VTE risk. Additionally, certain histologies such as membranous nephropathy confer higher thrombotic risk, but among measurable parameters, low serum albumin best correlates with thrombotic events.

In steroid‑resistant FSGS, especially when presenting at a younger age or with features suggesting a genetic cause, testing for monogenic podocytopathy is important because a confirmed genetic diagnosis alters management: many monogenic forms do not respond to immunosuppression and immunosuppressive toxicity can be avoided. Starting a calcineurin inhibitor (option A) or rituximab (option B) may be considered if a genetic cause is unlikely, but genetic testing should be considered prior to committing to further toxic immunosuppression. Plasmapheresis (option C) is reserved for antibody‑mediated diseases (e.g., recurrent FSGS post‑transplant in selected cases) rather than routine steroid‑resistant primary FSGS. Empiric cyclophosphamide (option D) is not the preferred next step without excluding a genetic cause. Therefore, genetic testing is the correct next investigation in steroid‑resistant FSGS.

Rituximab has emerged as a highly effective steroid‑sparing agent in steroid‑dependent or frequently relapsing MCD in adults, with good evidence for inducing sustained remission and reducing cumulative steroid exposure. Cyclophosphamide (option A) and calcineurin inhibitors (option B) are also effective steroid‑sparing options; cyclophosphamide is effective for inducing longer‑term remission but carries fertility and toxicity concerns, and calcineurin inhibitors require monitoring and relapse is common after withdrawal. Mycophenolate (option C) and azathioprine (option D) have less robust evidence compared with rituximab and the other options. Therefore, rituximab is the most evidence‑supported choice to reduce steroid burden in adult steroid‑dependent MCD.

Statins are first‑line therapy to reduce atherosclerotic cardiovascular risk in adults with chronic kidney disease and in nephrotic syndrome when indicated by overall cardiovascular risk; they reduce major atherosclerotic events. Fibrates (option A) may be used selectively for severe hypertriglyceridaemia to reduce pancreatitis risk but are not primary agents for atherosclerotic risk reduction and have increased myopathy risk when combined with statins. Bile acid sequestrants (option B) have limited efficacy and are poorly tolerated in many patients. Deferring lipid therapy until nephrotic remission (option D) risks prolonged exposure to high atherogenic lipoproteins; treating based on risk assessment is appropriate. Ezetimibe monotherapy (option E) is less effective than statin therapy; it may be used as an adjunct or if statin intolerance occurs. Therefore, statin therapy is the most appropriate evidence-based strategy.

When AL amyloidosis or monoclonal gammopathy is suspected in a nephrotic patient, the optimal initial laboratory evaluation is a serum free light chain assay together with serum and urine immunofixation electrophoresis. This combination maximises sensitivity for detecting a monoclonal light‑chain process. Urine dipstick (option B) is insensitive for light chains and does not replace immunofixation. Complement levels (option C), ANA/dsDNA (option D) and viral serology (option E) may be relevant in other causes of nephrotic syndrome but are not the best initial tests when AL amyloidosis is suspected. If these tests suggest a monoclonal process, referral to haematology and tissue diagnosis (e.g., fat pad or organ biopsy with Congo red and typing) are required.

For high‑risk patients with primary membranous nephropathy, contemporary guidelines increasingly support B‑cell depletion with rituximab as a first‑line targeted immunotherapy because of favourable efficacy and toxicity compared with older regimens. The Ponticelli regimen (option B: cyclophosphamide plus steroids) remains an effective alternative, particularly where rituximab is contraindicated or unavailable, but rituximab is often preferred due to a better safety profile. High‑dose glucocorticoids alone (option A) are not effective as monotherapy for membranous nephropathy. Mycophenolate (option C) has variable evidence and is not the preferred first‑line choice in high‑risk membranous disease. Plasmapheresis (option E) is not a standard primary therapy for membranous nephropathy.

An uncorrected bleeding diathesis (coagulopathy) is an absolute contraindication to percutaneous renal biopsy because of the high risk of life‑threatening haemorrhage; coagulopathy should be corrected before biopsy or an alternative diagnostic approach used. A solitary kidney (option A) is not an absolute contraindication—biopsy can be done with informed consent and experienced operators when the diagnostic benefit outweighs risk. Moderate controlled hypertension (option C) is a relative risk factor but not an absolute contraindication; it should be optimised before biopsy. A urinary tract infection (option D) may necessitate treatment before biopsy to reduce infection risk but is not an absolute contraindication in all circumstances. Advanced age (option E) increases procedural risk but is not an absolute contraindication.